Patents by Inventor Arie Horowitz

Arie Horowitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7029668
    Abstract: The present invention provides tangible means and methods for stimulation of angiogenesis via enhanced endothelial expression of core proteins having a syndecan-4 cytoplasmic region intracellularly. The tangible means include a prepared DNA sequence fragment having separate and individual DNA sequenced portions coding for an heparan sulfate binding extracellular domain, a central transmembrane domain, and a cytoplasmic domain coding for the syndecan-4 polypeptide. The prepared DNA sequence unitary fragment may be delivered to endothelial cells in-situ, both under in-vivo and/or in-vitro conditions, using suitable expression vectors including plasmids and viruses. The resulting transfected endothelial cells overexpress heparan sulfate binding, core proteins; and the resulting overexpression of these proteoglycan entities causes stimulation of angiogenesis in-situ.
    Type: Grant
    Filed: January 28, 2003
    Date of Patent: April 18, 2006
    Assignee: Beth Israel Deaconess Medical Center
    Inventors: Michael Simons, Ruediger Volk, Arie Horowitz
  • Patent number: 6852515
    Abstract: The present invention provides tangible means and methods for stimulation of angiogenesis via enhanced endothelial expression of core proteins having a syndecan-4 cytoplasmic region intracellularly. The tangible means include a prepared DNA sequence fragment having separate and individual DNA sequenced portions coding for an heparan sulfate binding extracellular domain, a central transmembrane domain, and a cytoplasmic domain coding for the syndecan-4 polypeptide. The prepared DNA sequence unitary fragment may be delivered to endothelial cells in-situ, both under in-vivo and/or in-vitro conditions, using suitable expression vectors including plasmids and viruses. The resulting transfected endothelial cells overexpress heparan sulfate binding, core proteins; and the resulting overexpression of these proteoglycan entities causes stimulation of angiogenesis in-situ.
    Type: Grant
    Filed: September 2, 1998
    Date of Patent: February 8, 2005
    Assignee: Beth Israel Deaconess Medical Center
    Inventors: Michael Simons, Rudiger Volk, Arie Horowitz
  • Patent number: 6815187
    Abstract: The present invention provides a methodology and compositions for stimulating angiogenesis in-situ within viable cells, tissues and organs comprising endothelial cells. The methodology focuses upon and controls the phosphorylation of the 183rd amino acid residue, serine, within the cytoplasmic domain and intracellular tail of transmembrane syndecan-4 proteoglycans which are then positioned at and through the cellular membrane of viable endothelial cells. By intervening and maintaining the 183rd residue in a non-phosphorylated state, a consequential cascade of intracellular events is initiated which result in a stimulation of angiogenesis in-situ.
    Type: Grant
    Filed: November 12, 1998
    Date of Patent: November 9, 2004
    Assignee: Beth Israel Deaconess Medical Center
    Inventors: Michael Simons, Arie Horowitz
  • Publication number: 20040013653
    Abstract: The present invention provides tangible means and methods for stimulation of angiogenesis via enhanced endothelial expression of core proteins having a syndecan-4 cytoplasmic region intracellularly. The tangible means include a prepared DNA sequence fragment having separate and individual DNA sequenced portions coding for an heparan sulfate binding extracellular domain, a central transmembrane domain, and a cytoplasmic domain coding for the syndecan-4 polypeptide. The prepared DNA sequence unitary fragment may be delivered to endothelial cells in-situ, both under in-vivo and/or in-vitro conditions, using suitable expression vectors including plasmids and viruses. The resulting transfected endothelial cells overexpress heparan sulfate binding, core proteins; and the resulting overexpression of these proteoglycan entities causes stimulation of angiogenesis in-situ.
    Type: Application
    Filed: January 28, 2003
    Publication date: January 22, 2004
    Inventors: Michael Simons, Ruediger Volk, Arie Horowitz